News

Sanofi, Regeneron fall after late-stage data for COPD therapy
Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...
Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...
Nasdaq2d
Regeneron and Sanofi Announce Mixed Results from Phase 3 AERIFY Trials for Itepekimab in COPD Patients
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...
Investing.com South Africa2d
Sanofi, Regeneron shares nosedive after mixed Itepekimab results
Investing.com -- Shares in Sanofi (EPA: SASY) (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) fell Friday after the pharmaceutical ...
Nasdaq2d
Regeneron, Sanofi: COPD Drug Itepekimab Meets Primary Goal In 1 Phase 3 Trial, But Fails In Another
Regeneron and Sanofi jointly develop Itepekimab under a ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Sanofi (SNY)’s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...
Sanofi to buy Vigil Neuroscience in $470M deal (update)
Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...
Sanofi granted FDA label expansion for MenQuadfi meningococcal shot for infants
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as ...
Nasdaq10d
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
French pharma giant Sanofi SNY recently announced that it has agreed to acquire Massachusetts-based biotech Vigil Neuroscience VIGL for a total equity value of around $470 million. The acquisition ...
Nasdaq11d
Sanofi to Acquire Vigil Neuroscience for Up to $10.00 per Share in Cash; Transaction Expected to Enhance Alzheimer’s Drug Development
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...